James Detore

Mr. DeTore has been a consulting chief financial officer to several high growth life science companies since 2017. Prior to this, he served as chief financial officer of Bluebird Bio and Proteostasis Therepeutics, in each case leading the company’s financing and investor relations strategies, helping to raise over $750 million in equity capital. He also served as vice president of corporate finance at Ironwood Pharmaceuticals where he worked directly on several debt and equity transactions, including the company initial public offering. Before that, he held senior financial roles at Genzyme. Mr. DeTore received his Master of Business Administration and bachelor’s degree in finance from Northeastern University.